Possible expansion of prior authorization to Medicare Fee For Services draws objections from American Academy of OphthalmologyMarch 30th 2023
The Centers for Medicare and Medicaid Services accepted comments on the proposed rule and several organizations, including the American Academy of Ophthalmology, chimed in with comments and offered suggestions.
Ocugen announces FDA Approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 Clinical Trial for the treatment of retinitis pigmentosa and Leber congenital amaurosisMarch 27th 2023
The FDA has approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with CEP290 gene mutations.
COPHy 2023: Debating the value of home monitoring as a management option for AMDMarch 25th 2023
The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.
COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye diseaseMarch 25th 2023
Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.
COPHy 2023: New restorative therapiesMarch 24th 2023
In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.
COPHy 2023: Durability associated with multi-target therapies is superior to anti-VEGF mono-target therapy in AMDMarch 24th 2023
Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®
Report: Physician payments should be tied to inflation-based indexMarch 16th 2023
To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.
ONL Therapeutics gets funding to move lead compound into Phase 2 clinical trialMarch 13th 2023
According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.
Iveric Bio releases data in geographic atrophy from avacincaptad pegol GATHER trialsMarch 9th 2023
According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.